Fly News Breaks for July 25, 2019
Jul 25, 2019 | 07:38 EDT
Oppenheimer analyst Jay Olson raised his price target for Sage Therapeutics to $200 from $170 after its SAGE-217 delivered positive open-label Phase 2 data in bipolar depression with 48% response rate. The analyst notes that Sage also presented a post-hoc analysis suggesting potential efficacy of SAGE-217 in treatment resistant depression. He reiterates an Outperform rating on the shares.
News For SAGE From the Last 2 Days
There are no results for your query SAGE